Terms: = Cervical cancer AND ERBB2, c-erb B2, 2064, P04626, ENSG00000141736, c-erbB2, HER-2/neu, HER2, TKR1, NEU, NGL, HER-2 AND Treatment
117 results:
1. [A Case of Breast cancer Complicated by Fibrous Dysplasia That Was Difficult to Differentiate from Bone Metastasis].
Makino Y; Otani A; Hikino H; Murata Y; Miura H; Harada A
Gan To Kagaku Ryoho; 2023 Dec; 50(13):1465-1467. PubMed ID: 38303309
[TBL] [Abstract] [Full Text] [Related]
2. Whether specific genetic feature predicted immunotherapy efficacy: A case report.
Chen J; Pang L; He L; Li T; Cheng X
Medicine (Baltimore); 2024 Jan; 103(2):e36922. PubMed ID: 38215117
[TBL] [Abstract] [Full Text] [Related]
3. Predictive and prognostic biomarkers in female genital tract tumours: an update highlighting their clinical relevance and practical issues.
Wong RW; Cheung ANY
Pathology; 2024 Mar; 56(2):214-227. PubMed ID: 38212229
[TBL] [Abstract] [Full Text] [Related]
4. Targeting her2-mutant metastatic cervical cancer with neratinib: Final results from the phase 2 SUMMIT basket trial.
Friedman CF; D'Souza A; Bello Roufai D; Tinker AV; de Miguel M; Gambardella V; Goldman J; Loi S; Melisko ME; Oaknin A; Spanggaard I; Shapiro GI; ElNaggar AC; Panni S; Ravichandran V; Frazier AL; DiPrimeo D; Eli LD; Solit DB
Gynecol Oncol; 2024 Feb; 181():162-169. PubMed ID: 38211393
[TBL] [Abstract] [Full Text] [Related]
5. Antibody-Drug Conjugates in Gynecologic cancers.
Anastasio MK; Shuey S; Davidson BA
Curr Treat Options Oncol; 2024 Jan; 25(1):1-19. PubMed ID: 38172449
[TBL] [Abstract] [Full Text] [Related]
6. Antibody-Drug Conjugates (ADC) in her2/neu-Positive Gynecologic Tumors.
McNamara B; Greenman M; Pebley N; Mutlu L; Santin AD
Molecules; 2023 Nov; 28(21):. PubMed ID: 37959808
[TBL] [Abstract] [Full Text] [Related]
7. Mechanism of gemcitabine combined with lobaplatin in interventional treatment of locally advanced cervical cancer.
Lin Y; Yang Q
Anticancer Drugs; 2024 Feb; 35(2):209-217. PubMed ID: 37948339
[TBL] [Abstract] [Full Text] [Related]
8. The value of multiparametric MRI combined with clinical prognostic parameters in predicting the 5-year survival of stage IIIC1 cervical squamous cell carcinoma.
Qin F; Pang H; Ma J; Xu H; Yu T; Luo Y; Dong Y
Eur J Radiol; 2023 Dec; 169():111181. PubMed ID: 37939604
[TBL] [Abstract] [Full Text] [Related]
9. Single-nucleus RNA sequencing reveals heterogenous microenvironments and specific drug response between cervical squamous cell carcinoma and adenocarcinoma.
Lin S; Sun Y; Cao C; Zhu Z; Xu Y; Liu B; Hu B; Peng T; Zhi W; Xu M; Ding W; Ren F; Ma D; Li G; Wu P
EBioMedicine; 2023 Nov; 97():104846. PubMed ID: 37879219
[TBL] [Abstract] [Full Text] [Related]
10. Efficacy and Safety of Trastuzumab Deruxtecan in Patients With her2-Expressing Solid Tumors: Primary Results From the DESTINY-PanTumor02 Phase II Trial.
Meric-Bernstam F; Makker V; Oaknin A; Oh DY; Banerjee S; González-Martín A; Jung KH; Ługowska I; Manso L; Manzano A; Melichar B; Siena S; Stroyakovskiy D; Fielding A; Ma Y; Puvvada S; Shire N; Lee JY
J Clin Oncol; 2024 Jan; 42(1):47-58. PubMed ID: 37870536
[TBL] [Abstract] [Full Text] [Related]
11. Establishment of a high-fidelity patient-derived xenograft model for cervical cancer enables the evaluation of patient's response to conventional and novel therapies.
Liu L; Wu M; Huang A; Gao C; Yang Y; Liu H; Jiang H; Yu L; Huang Y; Wang H
J Transl Med; 2023 Sep; 21(1):611. PubMed ID: 37689699
[TBL] [Abstract] [Full Text] [Related]
12. The role of sialylation in gynecologic cancers.
Yang ST; Liu CH; Chao WT; Liu HH; Lee WL; Wang PH
Taiwan J Obstet Gynecol; 2023 Sep; 62(5):651-654. PubMed ID: 37678990
[TBL] [Abstract] [Full Text] [Related]
13. Assessing the Genomic Landscape of cervical cancers: Clinical Opportunities and Therapeutic Targets.
Friedman CF; Ravichandran V; Miller K; Vanderbilt C; Zhou Q; Iasonos A; Vivek M; Mishra P; Leitao MM; Broach V; Sonoda Y; Kyi C; Zamarin D; O'Cearbhaill RE; Konner J; Berger MF; Weigelt B; Momeni Boroujeni A; Park KJ; Aghajanian C; Solit DB; Donoghue MTA
Clin Cancer Res; 2023 Nov; 29(22):4660-4668. PubMed ID: 37643132
[TBL] [Abstract] [Full Text] [Related]
14. Epidemiology of cervical cancer in elderly women: Analysis of incidence, treatment, and survival using German registry data.
Neumeyer S; Tanaka LF; Liang LA; Klug SJ
Cancer Med; 2023 Aug; 12(16):17284-17295. PubMed ID: 37403686
[TBL] [Abstract] [Full Text] [Related]
15. The differences in immune features and genomic profiling between squamous cell carcinoma and adenocarcinoma - A multi-center study in Chinese patients with uterine cervical cancer.
Li J; Xue X; Zhang Y; Ding F; Wu W; Liu C; Xu Y; Chen H; Ou Q; Shao Y; Li X; Wu F; Wu X
Gynecol Oncol; 2023 Aug; 175():133-141. PubMed ID: 37356314
[TBL] [Abstract] [Full Text] [Related]
16. Trastuzumab, leuprorelin, letrozole, and palbociclib as first-line therapy in her2-positive and hormone receptor-positive metastatic breast cancer: A case report.
Sun M; Cai L; Chen M
Medicine (Baltimore); 2023 Jun; 102(24):e33975. PubMed ID: 37327257
[TBL] [Abstract] [Full Text] [Related]
17. Efficacy of anti-her2 drugs in the treatment of patients with her2-mutated cancers: a systematic review and meta-analysis.
Zheng Y; Shen G; Zhang C; Huo X; Xin Y; Fang Q; Guan Y; Zhao F; Ren D; Liu Z; Wang M; Zhao J
Clin Exp Med; 2023 Nov; 23(7):3205-3216. PubMed ID: 37120775
[TBL] [Abstract] [Full Text] [Related]
18. Integrating antibody drug conjugates in the management of gynecologic cancers.
Chelariu-Raicu A; Mahner S; Moore KN; Lorusso D; Coleman RL
Int J Gynecol Cancer; 2023 Mar; 33(3):420-429. PubMed ID: 36878560
[TBL] [Abstract] [Full Text] [Related]
19. ROS1 as a possible prognostic biomarker of cervical adenocarcinoma: An exploratory analysis with next-generation sequencing.
Machida H; Matsuo K; Tanaka M; Kitatani K; Takase A; Yokoyama K; Kajiwara H; Yasaka M; Ikeda M; Yoshida H; Hirasawa T; Mikami M
Gynecol Oncol; 2023 Apr; 171():59-66. PubMed ID: 36804622
[TBL] [Abstract] [Full Text] [Related]
20. Investigational drugs for recurrent or primary advanced metastatic cervical cancer: what is in the clinical development pipeline?
Vergote I; Ray-Coquard I; Lorusso D; Oaknin A; Cibula D; Van Gorp T
Expert Opin Investig Drugs; 2023 Mar; 32(3):201-211. PubMed ID: 36803278
[TBL] [Abstract] [Full Text] [Related]
[Next]
